Cambrex Corp. CEO Sells $27,024 in Stock (CBM)
Cambrex Corp. (NYSE:CBM) CEO Steven M. Klosk sold 1,200 shares of Cambrex Corp. stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $22.52, for a total transaction of $27,024.00. Following the sale, the chief executive officer now directly owns 145,870 shares in the company, valued at approximately $3,284,992. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Cambrex Corp. (NYSE:CBM) traded down 1.72% on Friday, hitting $21.77. The stock had a trading volume of 293,627 shares. Cambrex Corp. has a 1-year low of $12.56 and a 1-year high of $23.88. The stock’s 50-day moving average is $21.42 and its 200-day moving average is $20.33. The company has a market cap of $667.9 million and a price-to-earnings ratio of 20.78.
Cambrex Corp. (NYSE:CBM) last issued its quarterly earnings data on Friday, August 1st. The company reported $0.35 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.28 by $0.07. The company had revenue of $98.00 million for the quarter, compared to the consensus estimate of $92.70 million. During the same quarter last year, the company posted $0.10 earnings per share. Cambrex Corp.’s revenue was up 59.2% compared to the same quarter last year. On average, analysts predict that Cambrex Corp. will post $1.11 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on CBM shares. Analysts at First Analysis downgraded shares of Cambrex Corp. from an “overweight” rating to an “equal weight” rating in a research note on Friday. Analysts at Longbow Research raised their price target on shares of Cambrex Corp. to $27.00 in a research note on Tuesday. They now have a “buy” rating on the stock.
Cambrex Corporation (NYSE:CBM) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.